Ending TB in Australia: Organizational challenges for regional tuberculosis programs.


Journal

Health policy (Amsterdam, Netherlands)
ISSN: 1872-6054
Titre abrégé: Health Policy
Pays: Ireland
ID NLM: 8409431

Informations de publication

Date de publication:
01 2020
Historique:
received: 16 04 2019
revised: 17 11 2019
accepted: 22 11 2019
pubmed: 11 12 2019
medline: 11 3 2021
entrez: 11 12 2019
Statut: ppublish

Résumé

The World Health Organization's End TB Strategy aims to eliminate tuberculosis (TB) by 2050. Low-burden countries such as Australia are targeted for early elimination (2035), which will require an increase in the intensity and scope of case finding and treatment of people with latent TB infection (LTBI). Because 80 % of TB disease in Australia occurs in metropolitan Sydney (New South Wales) and Melbourne (Victoria), the commitment to move towards elimination has major implications for TB programs in these jurisdictions. We report on a case study analysis that compares and contrasts key attributes of each of these healthcare organizations. Such analysis has important implications for all countries seeking to implement international agreements within local health structures. Differences in the organizational structure, culture and systems of care in NSW and Victoria may facilitate or create barriers to changes in organizational system functions, especially the way in which TB prevention and LTBI treatment is delivered. Ratification of global health treaties and the development of national strategies, alone, is insufficient for realizing the promised outcomes. Even in high income countries, global health agendas such as TB elimination can be complicated by differences in local system structure and funding. As the timelines tighten towards 2035, more work must be done to identify the organizational conditions and service models that will facilitate progress towards TB elimination.

Identifiants

pubmed: 31818484
pii: S0168-8510(19)30278-7
doi: 10.1016/j.healthpol.2019.11.009
pii:
doi:

Types de publication

Journal Article

Langues

eng

Pagination

106-112

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Chris Degeling (C)

Australian Centre for Health Engagement, Evidence and Values, Faculty of Social Science, University of Wollongong, NSW, Australia. Electronic address: degeling@uow.edu.au.

Jane Carroll (J)

Senior Medical Officer of the Commonwealth, Bupa Medical Visa Services, Sydney, NSW, Australia. Electronic address: Jane.Carroll@bupa.com.au.

Justin Denholm (J)

Victorian Tuberculosis Program and the Doherty Institute, University of Melbourne, VIC, Australia. Electronic address: justin.denholm@mh.org.au.

Ben Marais (B)

Western Sydney Local Health District and the Marie Bashir Institute, University of Sydney, NSW, Australia. Electronic address: ben.marais@health.nsw.gov.au.

Angus Dawson (A)

Sydney Health Ethics, School of Public Health and the Marie Bashir Institute, University of Sydney, NSW, Australia. Electronic address: angus.dawson@sydney.edu.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH